Brean Capital reiterated their buy rating on shares of Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) in a report published on Tuesday. The firm currently has a $7.00 price target on the biotechnology company’s stock.
Other analysts have also recently issued research reports about the company. Zacks Investment Research upgraded Conatus Pharmaceuticals from a hold rating to a buy rating and set a $2.25 price target for the company in a report on Wednesday, August 10th. Roth Capital started coverage on Conatus Pharmaceuticals in a report on Friday, July 1st. They set a buy rating for the company. Finally, FBR & Co reiterated an outperform rating and set a $16.00 target price on shares of Conatus Pharmaceuticals in a report on Tuesday, August 30th. Six analysts have rated the stock with a buy rating, The company currently has a consensus rating of Buy and a consensus target price of $9.21.
Shares of Conatus Pharmaceuticals (NASDAQ:CNAT) traded down 1.96% during trading on Tuesday, reaching $2.00. 34,440 shares of the company’s stock traded hands. The stock’s market capitalization is $44.14 million. Conatus Pharmaceuticals has a 1-year low of $1.40 and a 1-year high of $4.62. The company has a 50 day moving average price of $1.92 and a 200 day moving average price of $2.23.
Conatus Pharmaceuticals (NASDAQ:CNAT) last posted its quarterly earnings results on Wednesday, August 3rd. The biotechnology company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.08. During the same period in the previous year, the firm posted ($0.31) earnings per share. On average, equities analysts forecast that Conatus Pharmaceuticals will post ($1.34) EPS for the current fiscal year.
A number of institutional investors have recently added to or reduced their stakes in CNAT. Bank of New York Mellon Corp raised its position in Conatus Pharmaceuticals by 2.0% in the second quarter. Bank of New York Mellon Corp now owns 86,296 shares of the biotechnology company’s stock valued at $178,000 after buying an additional 1,668 shares during the period. AXA raised its position in shares of Conatus Pharmaceuticals by 1.4% in the second quarter. AXA now owns 1,085,775 shares of the biotechnology company’s stock worth $2,237,000 after buying an additional 14,939 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Conatus Pharmaceuticals by 3.5% in the second quarter. Vanguard Group Inc. now owns 448,938 shares of the biotechnology company’s stock worth $925,000 after buying an additional 15,300 shares during the last quarter. 22.80% of the stock is currently owned by hedge funds and other institutional investors.
Conatus Pharmaceuticals Company Profile
Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.
Receive News & Ratings for Conatus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.